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Abstract The present study assessed the discriminative 
stimulus effects of the delta-opioid agonist [D-Pen2-D - 
PenS]enkephalin (DPDPE) in pigeons. Food-restricted 
pigeons were trained to discriminate between ICV injec- 
tions of 100 gg [D-Pen2-D-PenS]enkephalin (DPDPE) and 
saline in a two-key operant procedure; acquisition of dis- 
criminative control was rapid (14-28 daily sessions). [D- 
Ser 2, Leu 5, Thr6]enkephalin (DSLET) and [D-Ala2]del - 
torphin II, peptides selective for delta-opioid receptors, 
produced discriminative stimulus effects similar to 
DPDPE, and were approximately equipotent to DPDPE. 
The non-peptidic, delta-opioid agonist BW373U86 
(0.032-100 mg/kg, IM) partially generalized to DPDPE. 
The kappa-opioid agonist U69,593 (0.01-1 mg/kg, IM), 
and the mu-opioid agonists, DAMGO (0.1-3.2 gg, ICV) 
and morphine (1-10 mg/kg, IM), did not produce dis- 
criminative stimulus effects similar to DPDPE, up to 
doses that markedly decreased response rates. Nattrin- 
dole (0.1 mg/kg, IM), an antagonist selective for delta- 
opioid receptors, produced approximately a 30-fold re- 
duction in the potency of DPDPE. DPDPE's discrimina- 
tive stimulus effect in pigeons appears to be mediated 
through a delta-opioid receptor; this effect may provide a 
procedure for assessing delta-opioid receptor function in 
vivo. 
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Introduction 
Opioids produce their effects through three major types of 
opioid receptors, ran, kappa, and delta. Drug discrimina- 
tion studies using receptor-selective agonists and antago- 
nists have made important contributions in characterizing 
these receptors. Distinct discriminative stimulus effects of 
mu- and some kappa-opioid agonists have been character- 
ized in pigeons. For example, bremazocine produced dis- 
criminative stimulus effects similar to those of another 
highly selective kappa agonist, U50,488, but neither pro- 
duced morphine-like discriminative stimulus effects (Pick- 
er and Dykstra 1987; although some kappa-opioid ago- 
nists do produce morphine-like discriminative effects, see 
Herling et al. 1980). A larger dose of naloxone is required 
to reduce the potency of U50,488 as a discriminative stim- 
ulus than is required to reduce morphine's potency (Picker 
and Dykstra 1987). Discriminative stimulus effects of del- 
ta-opioid receptor agonists, however, have not been stud- 
ied extensively. One possible reason for the paucity of 
drug discrimination information on delta-opioid agonists 
is that most agonists at delta-opioid receptors are peptides, 
have difficulty crossing the blood-brain barrier, and proba- 
bly need to be administered centrally. 
To date, only one study has demonstrated discrimina- 
tive stimulus effects mediated through a delta-opioid re- 
ceptor (Comer et al. 1993). The discriminative stimulus 
effects of IM BW373U86 were antagonized by small 
doses of naltrindole, which is more potent in antagoniz- 
ing delta-opioid effects than mu- or kappa-opioid medi- 
ated effects. Interestingly, central administration of the 
prototypic delta-opioid receptor agonists DPDPE and 
DSLET did not produce a discriminative stimulus similar 
to that of BW373U86. Additionally, a portion of 
BW373U86's discriminative stimulus effects were 
shared with mu-opioid agonists. Systemically adminis- 
tered morphine, alfentanil, and etonitazene all produced 
partial generalization to the BW373U86 discriminative 
stimulus, and BW373U86 partially generalized to mor- 
phine in pigeons trained to discriminate 5.6 mg/kg mor- 
phine from saline. 
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Few studies have establ ished discriminative stimulus 
effects based on centrally administered compounds  (see, 
however,  Jewett et al. 1991, 1993). Some studies have 
assessed the ability o f  proposed delta-opioid agonists 
(e.g. D-Ala 2, D-LeuS-enkephalin; D A D L E )  to produce 
discriminative stimulus effects similar to mu-opioid  ago- 
nists. In rats, centrally administered D A D L E  produced 
discriminative stimulus effects similar to fentanyl, but 
not e thylketocyclazocine (Shearman and Herz 1982). In 
rats trained to discriminate mol~hine  f rom saline, ICV 
D A D L E  produced a morphine-l ike discriminative stimu- 
lus but ICV [D-Pen2-L-PenS]enkephalin (DPLPE),  which 
has greater selectivity for delta-opioid receptors than 
DADLE,  did not (Ukai and Hol tzman 1988). That  
D P L P E  did not produce its effects through mu- or kappa-  
opioid receptors does not prove that DPLPE,  and ago-  
nists more  selective than D P L P E  for  delta-opioid recep- 
tors, produce their effects through delta-opioid receptors. 
The  goals o f  the present study were to establish a dis- 
crimination based on the central administration o f  
DPDPE,  a peptide highly selective for delta opioid re- 
ceptors (Mosberg  et al. 1983). The ability o f  selective 
agonists for mu-  (DAMGO,  morphine),  kappa-  
(U69,593) or delta- (BW373U86,  DSLET,  deltorphin II) 
opioid receptors and a non-opioid (cocaine) to produce  
discriminative stimulus effects similar to D P D P E  was 
also assessed. To demonstrate  further the receptor  selec- 
tivity o f  D P D P E ' s  discriminative stimulus effects, exper-  
iments were performed using naltrindole, an antagonist  
selective for delta-opioid receptors. 
Materials and methods 
Subjects 
Ten experimentally naive white Carneaux pigeons were used in 
the present studies. All pigeons were maintained at 80% of their 
free-feeding weight by mixed grain availability during experimen- 
tal sessions and Purina Pigeon Checkers received post-session in 
the home cage. All subjects were housed individually with water 
and grit freely available. 
Apparatus 
Experimental sessions were conducted in operant chambers 
(36x28x33 cm high) equipped with three translucent response 
keys (2.4 cm diameter) that could be illuminated by 7-W red lights 
located behind each key. Food was presented via a hopper that piv- 
oted into an opening located below the center response key. Oper- 
ant chambers were located in ventilated, sound-attenuating cubi- 
cles. Experimental contingencies were arranged and data were re- 
corded by MED-PC software (MED Associates, East Fairfield, 
Vt.) and an IBM PC computer, located in an adjacent room. 
Surgery 
The details of the surgical procedure have been described previ- 
ously (France et al. 1985). Briefly, pigeons were anaesthetized 
with 2.5-2.75 ml/kg Chloropent (chloral hydrate and pentobarbit- 
al: Fort Dodge Laboratories, Fort Dodge, Iowa) and 8 mg/kg ket- 
amine. A chronic, indwelling cannula (Plastic Products, Roanoke, 
Va.) was implanted in the right lateral ventricle using stereotaxic 
procedm'es and a Rezvin adapter (Karten and Hodos 1967). A 28 g 
dummy cannula was inserted into the guide cannula except during 
ICV injections. The patency of the cannula was assessed by ICV 
injection of radioopaque dye (Conray: Mallinckrodt, St Louis, 
Mo.) or by catalepsy induced by 17.2 gg 2-amino-5-phosphono- 
valerate (Koek et al. 1985; AP5; Sigma, St Louis, Mo.). 
Procedures 
Discrimination training 
Pigeons were initially trained to peck a single (center) illuminated 
key to obtain access to mixed grain by the method of successive 
approximations. Initially, one key-peck produced food access. 
This response requirement was gradually increased until 20 key- 
pecks were required to produce access to mixed grain (FR 20; 
Ferster and Skinner 1957). When responding was reliable (greater 
than 1.5 responses/s), pigeons were implanted with cannulae in the 
right lateral ventricle. Following surgery and a 1-week recovery 
period, discrimination training began. 
Pigeons were trained to discriminate between an ICV injection 
of 100 gg DPDPE and an equal volume (10 gl) of saline. Daily 
training sessions consisted of one trial per day. The first three 
training sessions were preceded by an injection of saline, after 
which the pigeon was placed in the operant chamber for 10 min. 
During this time, the chamber was dark, and responses had no pro- 
grammed consequences. At the end of the pretreatment time, the 
left key was illuminated, and 20 responses on the key produced 5- 
s access to mixed grain. The training session continued until 25 re- 
inforcers were earned or 30 rain, whichever occurred first. The 
next three training trials were preceded by an injection of 100 gg 
DPDPE, and following the 10-min pretreatment period, only the 
right key was illuminated. Pecks on this key produced access to 
mixed grain under an FR 20. Following these six sessions, dis- 
crimination training began. These training sessions consisted of an 
injection of either DPDPE (100 ~tg) or saline, the 10-min pretreat- 
ment period, and a 30-rain response period. Both response keys 
were illuminated during the response period. Responses on the in- 
jection-appropriate key (right following DPDPE; left following sa- 
line administration) were reinforced by 5-s access to mixed grain 
under an FR 20. Responses on the incorrect key had no pro- 
grammed consequences. Sessions preceded by DPDPE and saline 
alternated randomly with the restriction that no more than two 
consecutive sessions of DPDPE or saline administration occurred. 
Discriminative control was defined as 1) greater than 50% of 
the responses prior to the first reinforcer delivery, and 2) greater 
than 90% of the responses for the total session, on the injection- 
appropriate key. Additionally, response rates were required to be 
greater than one response/s. Before discrimination testing began, 
subjects were required to meet these criteria for eight consecutive 
training sessions. Thereafter, tests were conducted whenever crite- 
ria were met for two consecutive sessions (a session preceded by 
DPDPE, and a session preceded by saline administration). 
Discrimination testing 
A single dosing procedure was used to assess the time course of 
DPDPE's (100 gg) discriminative stimulus effects in five pigeons. 
The stimulus effects were evaluated 0, 5, I0, 20, 40, 80, t60, and 
320 rain after a single injection of 100 gg DPDPE. At each time 
point, a response period was initiated during which pigeons ob- 
tained access to food by for pecking either response key under an 
FR 20. The response period continued for 5 rain, or until ten rein- 
forcers were delivered. 
Tests assessing the ability of DPDPE and other drugs to either 
produce discriminative stimulus effects similar to those of 100 gg 
DPDPE, or to antagonize the discriminative stimulus effects of 
DPDPE involved the use of cumulative dosing procedures. The 
testing procedure consisted of several trials composed of a 10-rain 
time-out period, and a response period. During the response peri- 
od, 20 responses on either key resulted in food presentation, and N t o o  
o continued for 5 min, or until ten reinforcers were delivered. After "c 
each trial, additional drug was administered (in 1/2 or 1/4 log unit ~- g 8 0  
increments) and a new trial began. This sequence continued until & 0~ 
responding was reduced to less than 0.3 responses/s or until the ~- = 60 
solubility limit of the test drug precluded additional testing. Two ~: g- 
groups of pigeons (n=5 per group) were used in the present stud- ~_ ~ 40 
ies. In one group, tests were conducted with DPDPE, DSLET, and ITL 
deltorphin II (all administered ICV). These pigeons also received c~ 2o 
IM injections of morphine, U69,593 and BW373U86 prior to test 
sessions. Another group of pigeons were tested with increasing o 
doses of DPDPE (ICV), DAMGO (ICV), and cocaine (IM). Addi- 
tionally, these pigeons received naltrindole (IM) 15 rain prior to 
increasing doses of DPDPE. 
Data analysis 
Results are presented as the mean (_+SEM) percentage of respons- 
es on the DPDPE-appropriate key as a function of dose. Com- 
pounds were considered to have partially generalized to DPDPE if 
they resulted in greater than 10%, but less than 90% DPDPE-ap- 
propriate responding. Compounds completely generalized to 
DPDPE if they resulted in at least 90% responding on the DPDPE- 
appropriate key. Response rates are expressed as means (+SEM) 
and are plotted as a function of dose administered. EDs0s were cal- 
culated using procedure #8 in the Pharmacological Calculation 
System of Tallarida and Murray (i987). This procedure does not 
exclude data points less than 20% or greater than 80% effect lev- 
els. Reductions in DPDPE's potency by naltrindole are expressed 
as a dose ratio (DR) between the EDs0 of DPDPE in the presence 
of 0.1 mg/kg naltrindole and the EDs0 of DPDPE alone. EDs0 val- 
ues for DPDPE and DPDPE in combination with naltrindole were 
considered to be significantly different if the 95% confidence lim- 
its did not overlap. In vivo apparent pK B values were determined 
for naltrindole in combination with DPDPE using the equation 
pKB=-log [B/(DR-1)] (Negus et al. 1993). The variable "B" 
equals the dose of naltrindole in mot/kg. 
Drugs 
[D-Pen 2, D-PenS]enkephalin, [D-Ser 2, Leu 5, Thr6]enkephalin 
(DSLET), [D-Ala2]deltorphin II (all synthesized by H. I. Mosberg 
and colleagues), U69,593 (Upjohn Co., Kalamazoo, Mich.), mor- 
phine sulfate (Mallinckrodt, St Louis, Mo.), [D-AIa 2, NMePhe 4- 
Met(O)5-(ol)]enkephalin (DAMGO) (Sigma, St Louis, Mo.), naltr- 
indole and cocaine (National Institute on Drug Abuse, Rockville, 
Md.) were dissolved in sterile water or saline (0.9%). 
Results 
DPDPE acquisition and duration 
of discriminative effects 
Pigeons rapidly learned to discriminate DPDPE from sa- 
line. Stimulus control was attained in an average of 22 dai- 
ly sessions (range 1 4 2 8 )  from the beginning of the 
"choice" procedure to the session immediately preceding 
the eight consecutive sessions demonstrating stimulus con- 
trol. During these eight sessions, every pigeon averaged 
greater than 92% injection-appropriate responding prior to 
the first reinforcer, and greater than 97% injection-appro- 
priate responding for the entire session. Response rates 
were unaffected following administration of 100 btg 
DPDPE (2.0+0.2 r/s) or saline (2.2+0.3 r/s). DPDPE pro- 
duced dose-dependent increases in DPDPE-appropriate re- 
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Fig. 1 A DPDPE dose-effect curve in pigeons trained to discrimi- 
nate 100 gg DPDPE from saline. Response rates were not affected 
by DPDPE administration (data not shown). B Time course of the 
discriminative stimulus effects of 100 gg DPDPE. Points are 
means (--+-SEM), n=5 
sponding (Fig. 1, panel A). Following 32 btg DPDPE, four 
of  five pigeons responded the DPDPE-appropriate key, and 
complete generalization occurred after 100 btg DPDPE. 
Subjects responded on the saline-appropriate key following 
administration of ICV saline (10 btl, ICV). 
The training dose of DPDPE (100 gg) had a rapid onset 
and long duration of action (Fig. 1, panel B). Four of  five 
pigeons responded exclusively on the DPDPE-appropriate 
key immediately after DPDPE administration. All subjects 
responded on the DPDPE-appropriate key 5 rain after ad- 
ministration, and responded on this key up to 80 rain after 
DPDPE administration. After 160 rain, only 25% of the re- 
sponses were emitted on the DPDPE-appropriate key. No 
DPDPE-appropriate responding was observed 320 rain af- 
ter its administration. Response rates were not affected by 
this dose of DPDPE (data not shown). Subjects responded 
on the saline-appropriate key following administration of 
ICV saline (10 gl, ICV) at all time points tested. 
Discrimination tests 
DSLET and deltorphin II, administered ICV, caused a dose- 
dependent increase in DPDPE-appropriate responding 
(Fig. 2, top panel). DSLET was 10- to 30-fold more potent 
than deltorphin II and DPDPE in tt~ee of the pigeons test- 
ed, but DPDPE, DSLET, and deltorphin II resulted in great- 
er than 90% DPDPE-appropriate responding in all pigeons 
following 100 gg. Response rates were not affected by any 
doses of DSLET and deltorphin II tested. No DPDPE-ap- 
propriate responding was observed following ICV injec- 
tions of DAMGO, although doses of 1 btg or greater mark- 
edly reduced responding (Fig. 2, bottom panel). 
The ability of  mu- and kappa-opioids and cocaine to 
produce a discriminative stimulus similar to DPDPE was 
also assessed. Intramuscularly administered morphine, 
U69,593, and cocaine did not produce discriminative 
stimulus effects similar to those of  DPDPE (Fig. 3) al- 
though these drugs markedly reduced responding. On the 
other hand, BW373U86, an agonist selective for delta- 
opioid receptors, produced 30-60% DPDPE-appropriate 
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Fig. 2 Dose-effect curves for ICV Deltorphin II (Delt. I1), DSLET 
and DAMGO in pigeons trained to discriminate DPDPE (100 gg) 
from saline. Top panel: ordinate: percentage of DPDPE-appropri- 
ate responses. Abscissa: agonist of dose (log scale). Bottom panel: 
response rate expressed in responses/s as a function of dose. 
Points are means (+SEM), n=5 
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Fig. 3 Dose-effect curves for IM morphine, U69,593, BW373U86 
and cocaine in pigeons trained to discriminate ICV DPDPE 
(100 gg) from saline. Top panel: percentage of DPDPE-appropri- 
ate responses. Bottom panel: response rate (responses/s). Points 
are means (_+SEM), n=5 
Naltrindole antagonism of DPDPE discriminative 
stimulus effects 
As shown in Fig. 4, administration of increasing doses of 
DPDPE produced dose-related increases in DPDPE-ap- 
propriate responding. Complete generalization (>90% 
DPDPE-appropriate responding) occurred after adminis- 
tration of 32 gg DPDPE in these pigeons. Response rates 
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Fig. 4 Effects of naltrindole (0.01 and 0.1 mg/kg) on the discrimi- 
native stimulus and rate-decreasing effects of DPDPE. Top panel: 
percentage of DPDPE-appropriate responses. Bottom panel: re- 
sponse rate (responses/s). Points are means (_+SEM), n=5 
were unaffected following 1-100 gg DPDPE, but re- 
sponding was suppressed following 320 gg. 
Pretreatment with naltrindole (0.01-0.1 mg/kg IM) 
produced a dose-dependent shift in the discriminative 
stimulus effects of DPDPE (Fig. 4). Naltrindole 
(0.1 mg/kg, IM), produced approximately a 30-fold re- 
duction in the potency of DPDPE to produce its discrim- 
inative stimulus and response rate decreasing effects. 
The apparent pK R value for naltrindole (0.1 mg/kg) 
against DPDPE was 8.3. 
Discussion 
The goals of  the present studies were to establish 
DPDPE as a discriminative stimulus and to determine 
the opioid receptor type mediating this effect. The pres- 
ent studies demonstrate that DPDPE was discriminable, 
and that its discriminative stimulus effects were mediat- 
ed through a delta-opioid receptor. Administration of the 
peptidic, delta-opioid agonists DSLET and deltorphin II 
resulted in DPDPE-appropriate behavior. DPDPE, 
DSLET and deltorphin II were equipotent in producing 
DPDPE-like discriminative stimulus effects in pigeons, 
although DSLET was more potent in three of five pi- 
geons tested. In mice, DPDPE and deltorphin II both 
produced antinociceptive effects, assessed using the 
warm-water tail-withdrawal assay, and both were antago- 
nized by delta-receptor-selective antagonists (e.g., Jiang 
et al. 1990). In mice, deltorphin II was 3-fold more po- 
tent than DPDPE in producing antinociceptive effects, 
and tolerance developed to deltorphin II and DPDPE, but 
no cross-tolerance was found between them, suggesting 
that these effects were produced through different sub- 
types of delta-opioid receptors (Mattia et al. 1991). In 
the present study, the finding that deltorphin II and 
DSLET produced discriminative stimulus effects similar 
to DPDPE suggests that a similar receptor type mediates 
this effect in pigeons. 
Only one previous study has described the acquisition 
of discriminative stimulus effects mediated through del- 
ta-opioid receptors in pigeons (Comer et al. 1993). Al- 
though BW373U86's  discriminative stimulus effects 
were antagonized by small doses of  naltrindole, its stim- 
ulus effects, were partially mediated through mu-opioid 
receptors. The mu-opioid agonists morphine, alfentanil, 
and etonitazene produced some BW373U86-appropriate 
responding. Also, BW373U86 produced some morphine- 
appropriate responding. These results suggested that mu- 
opioid receptors are at least partially involved in the dis- 
criminative stimulus effects of BW373U86. In pigeons 
trained to discriminate DPDPE from saline, BW373U86 
produced some DPDPE-like discriminative stimulus ef- 
fects over a wide dose range. Taken together, these find- 
ings are consistent with the notion that BW373U86's dis- 
criminative stimulus effects are complised of  both a del- 
ta-opioid component and mu-opioid component. 
Discrimination tests did not provide evidence for oth- 
er opioid receptor mechanisms or cocaine-related mecha- 
nisms modulating the discriminative stimulus effects of  
DPDPE. Mu-opioid agonists DAMGO (ICV) and mor- 
phine (IM) failed to produce a discriminative stimulus 
effect similar to DPDPE at active doses. The kappa-opio- 
id agonist U69,593 and cocaine (IM) did not produce 
DPDPE-like discriminative stimulus effects. In rats, 
some studies have revealed interactions between delta- 
opioid receptor mechanisms and cocaine related mecha- 
nisms. For example, in rats trained to discriminate co- 
caine from saline, DPLPE produced discriminative stim- 
ulus effects similar to those of cocaine (Ukai et al. 1993). 
In addition, naltrindole and naltriben, antagonists selec- 
tive for delta-opioid receptors produced a small (2-fold), 
but significant, reduction in the potency of cocaine to 
produce its discriminative stimulus effects in rats (Su- 
zuki et al. 1994). Taken together, these studies suggest 
delta-opioids can modulate the discriminative stimulus 
effects of  cocaine in rats. In the present study, however, 
we found no evidence for cocaine producing discrimina- 
tive stimulus similar to those of DPDPE in pigeons. 
In order to evaluate further the notion that delta-opio- 
id receptors mediate the discriminative stimulus effects 
of DPDPE, studies were performed with naltrindole, an 
antagonist selective for delta-opioid receptors. A small 
dose of naltrindole (0.1 mg/kg, IM) antagonized the dis- 
criminative stimulus and rate decreasing effects of 
DPDPE by approximately 30-fold. Small doses of  naltr- 
indole have previously been found to antagonize the dis- 
criminative stimulus of BW373U86, but not those of the 
mu-opioid agonist morphine (Comer et al. 1993). Also, 
naltrindole was 32- to 100-fold more potent in antago- 
nizing the discriminative stimulus and rate-decreasing 
effects of DPDPE than reducing the potency of  morphine 
to produce discriminative stimulus (Comer et al. 1993) 
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and response rate decreasing effects (D.C. Jewett, un- 
published observations). The apparent pK B value for 
naltrindole with DPDPE (8.3) was similar to the appar- 
ent pA 2 value obtained by Comer et al. (1993) for naltr- 
indole with BW373U86 in the pigeon (7.9_+0.5). 
The discriminative stimulus effects of DPDPE were 
acquired rapidly. Subjects learned to discriminate 
DPDPE from saline in 14-28 sessions. Few studies have 
established discriminative stimulus effects using a cen- 
trally administered drug. In those instances, the training 
drug's discriminative stimulus effects have been rapidly 
acquired (within 14 daily sessions; Jewett et al. 1991, 
1993). At present, it is unclear if  discriminative stimulus 
effects are acquired faster via central administration. 
Further research with a variety of compounds, especially 
those that can be established as discriminative stimuli by 
systemic administration, would be useful to address this 
issue. 
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